Media coverage about Cronos Group (NASDAQ:CRON) has been trending positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cronos Group earned a media sentiment score of 0.28 on Accern’s scale. Accern also gave news stories about the company an impact score of 47.4401770156474 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the media headlines that may have effected Accern’s analysis:

A number of research firms recently issued reports on CRON. Canaccord Genuity lowered Cronos Group from a “hold” rating to a “sell” rating in a report on Tuesday, May 1st. GMP Securities upgraded Cronos Group from a “hold” rating to a “buy” rating in a report on Friday, April 6th. Finally, Beacon Securities restated a “buy” rating on shares of Cronos Group in a research note on Friday, May 4th.

Cronos Group traded down $0.22, reaching $6.80, during midday trading on Monday, Marketbeat reports. The company’s stock had a trading volume of 46,082 shares, compared to its average volume of 3,984,888. Cronos Group has a fifty-two week low of $1.00 and a fifty-two week high of $11.90. The company has a debt-to-equity ratio of 0.04, a current ratio of 20.68 and a quick ratio of 15.92. The stock has a market cap of $1.24 billion and a PE ratio of 679.00.

Cronos Group (NASDAQ:CRON) last posted its quarterly earnings results on Monday, April 30th. The company reported $0.01 earnings per share for the quarter. Cronos Group had a return on equity of 2.74% and a net margin of 35.12%. The company had revenue of $1.27 million for the quarter. research analysts expect that Cronos Group will post -0.01 earnings per share for the current fiscal year.

About Cronos Group

Cronos Group Inc, formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations (?MMPR?). The firm typically invests in companies based in Canada.

Insider Buying and Selling by Quarter for Cronos Group (NASDAQ:CRON)

Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with's FREE daily email newsletter.